{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-26-153923","form_type":"8-K","ticker":"CRBP","cik":"0001595097","company_name":"Corbus Pharmaceuticals Holdings, Inc.","filed_at":"2026-04-14T23:59:59+00:00","discovered_at":"2026-05-14T18:02:32.541221+00:00","generated_at":"2026-05-15T06:22:28.069356+00:00","sec_items":["7.01","8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Corbus completes enrollment in CANYON-1 Phase 1b trial of CRB-913 for obesity; on track for summer 2026 data","bullets":["Last patient enrolled and completed first visit in CANYON-1 Phase 1b trial of CRB-913, a peripherally restricted oral CB1 inverse agonist.","Trial is a 16-week, placebo-controlled, dose-ranging study (n=240) with 20, 40, and 60 mg QD cohorts; completion expected summer 2026.","Phase 1a data showed 2.9% placebo-adjusted weight loss at Day 14 in obese cohort, with no vomiting, constipation, or nausea reported.","Neuropsychiatric assessments (CSSRS, PHQ-9, GAD-7) were negative across all cohorts."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-26-153923","json":"https://secwatch.observer/filing/0001193125-26-153923.json","markdown":"https://secwatch.observer/filing/0001193125-26-153923.md","text":"https://secwatch.observer/filing/0001193125-26-153923.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/0001193125-26-153923-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1595097/000119312526153923/crbp-20260414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-15T06:22:28.069356+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}